Navigation Links
Researchers seeking to identify Alzheimer's risk focus on specific blood biomarker
Date:9/9/2008

NEW YORK A simple blood test to detect whether a person might develop Alzheimer's disease is within sight and could eventually help scientists in their quest toward reversing the disease's onset in those likely to develop the debilitating neurological condition.

Building on a study that started 20 years ago with an elderly population in Northern Manhattan at risk or in various stages of developing Alzheimer's disease, the Columbia research group has yielded ground-breaking findings that could change the way the disease is treated or someday prevent it. These findings suggest that by looking at the blood doctors may be able to detect a person's predisposition to developing the dementia-inducing disease that robs a person of their memory and ability carry out tasks essential to life.

Results presented online in the Proceedings of the National Academy of Sciences during the week of Sept. 8, 2008 suggest that individuals with elevated levels of a certain peptide in the blood plasma, Amyloid Beta 42 (A42), are at increased risk of developing Alzheimer's disease and that the decline of A42 in the bloodstream may reflect the compartmentalization or "traffic jam" of A42 in the brain, which occurs in the brain's of people with Alzheimer's.

"To date, A42 levels have measured most reliably in the cerebrospinal fluid, which is more difficult to collect than blood," said Nicole Schupf, Ph.D., Dr.P.H., associate professor of clinical epidemiology at Columbia University Medical Center and lead author of the paper. "Blood draws can be done with relative ease and greater frequency than spinal taps, which is typically the way cerebrospinal fluid is collected."

In this study, researchers found that plasma levels of A42 appear to increase before the onset of Alzheimer's disease and decline shortly after the onset of dementia. Researchers surmise that A42 may become trapped in the brain, which could account for the decrease in levels post-dementia.

The principal investigator on the Northern Manhattan study, Richard Mayeux, M.D., M.S., professor of neurology, psychiatry, and epidemiology, and co-director of the Taub Institute of Research on Alzheimer's Disease and the Aging Brain at CUMC, likens the finding to something similar that is seen in heart attack patients, who typically have elevated lipid levels in their bloodstream prior to a heart attack, but post-heart attack lipid levels may decrease.

Using more specific antibodies developed by the Ravetch Laboratory at Rockefeller University, the researchers were able to hone in on the most detrimental form of amyloid compound, the protofibrillar form of A, according to Dr. Mayeux, who is the senior author of this paper.

While the cognitive impairments of Alzheimer's can be monitored throughout the disease course, clinicians have had no reliable way to monitor the pathologic progression of the disease. Being able to reliably measure A levels in the blood could provide clinicians with a tool that forecasts the onset of Alzheimer's much earlier. Earlier detection would of course be an important step in combating the disease, researchers said.


'/>"/>

Contact: Alex Lyda
mal2133@columbia.edu
212-305-0820
Columbia University Medical Center
Source:Eurekalert  

Related biology news :

1. ISU researchers help map first plant-parasitic nematode genome sequence
2. Collaboration between researchers yields more comprehensive portrait of brain cancer
3. Tel Aviv University researchers create new stem cell screening tool
4. Hopkins researchers piece together gene network linked to schizophrenia
5. TGen and Washington University researchers discover new approach to treating endometrial cancer
6. Researchers devise means to create blood by identifying earliest stem cells
7. Researchers discover atomic bomb effect results in adult-onset thyroid cancer
8. Antidepressants need new nerve cells to be effective, UT Southwestern researchers find
9. Indiana U researchers launch social networking and research management tool for scientists
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. Munich researchers discover key allergy gene
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers seeking to identify Alzheimer's risk focus on specific blood biomarker
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology: